The MyRisk^™ Hereditary Cancer Test helps you make the decisions that matter most

Myriad is your trusted advisor

• 27+ years of experience in hereditary cancer testing
• Analytically validated high-throughput sequencing
• Industry leading variant classification program
• Lifetime commitment to variant classification & result updates

Commitment to providing broad patient access

• Myriad works directly with patients to provide up front clarity and resolve questions about cost (cost estimator coming soon)
• Affordability options personalized to patients’ unique needs
• 97% of private insurance have coverage for testing
• Pre-test counseling services to educate patients on HC testing (post-test coming soon)
• 90% of patients have or will qualify for a payment of $100 or less

Data-sharing, discovery and insights

Patients and providers are at the center of our mission to make genetic testing and data-driven medical information more widely available. Beginning in Spring 2023, we will be sharing clinically impactful hereditary cancer and prenatal data submissions with the ClinVar public database. We will continue to identify ways to leverage our datasets as we work to advance health and well-being for all, and enable healthcare providers to better detect, treat, and prevent disease.